COMMUNIQUÉS West-GlobeNewswire

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
24/11/2025
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate [...]
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
24/11/2025
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
JenaValve Announces New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
24/11/2025
IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from an expanded cohort of 700 [...]
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
24/11/2025
--Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- [...]
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
24/11/2025
Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
24/11/2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care [...]
Philips launches next-generation web-based diagnostic viewer for fast, secure imaging data access anywhere
24/11/2025
November 24, 2025 New viewer offers full radiology capabilities, interfaces with AI and interactive reporting module to streamline workflows Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global [...]
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025
Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ET ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard [...]
Korean distributor agreement with DK Healthcare in South Korea
24/11/2025
Expanding commercial reach and advancing lung imaging innovation in Asia-Pacific DURHAM, NC and LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial- [...]
Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results
24/11/2025
Clinical validation successfully completed with Mayo Clinic Platform’s Validate program – marking the final clinical requirement prior to FDA 510(k) submission EchoSolv HF validation met the primary endpoint, delivering [...]
Curaechoice Selects CVS Caremark at its PBM
24/11/2025
All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies Nationwide Starting January 1 Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost [...]
Providence Saint John’s Earns Magnet Recognition, The Gold Standard in Nursing Excellence
24/11/2025
SANTA MONICA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Providence Saint John’s Health Center has achieved Magnet ® recognition, the nation’s highest honor for nursing excellence, awarded by the American Nurses [...]
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
24/11/2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami
24/11/2025
Media Release COPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Citi Global Healthcare [...]
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
24/11/2025
-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio <2. Achieved [...]
Cannara Biotech réalise des revenus et une rentabilité records pour l’exercice 2025 et affiche pour la première fois un solde positif de bénéfices non répartis
24/11/2025
R ésultats financiers records pour l'exercice 2025 : total des produits, déduction faite des taxes et de 107,3 millions de dollars, BAIIA ajusté de 28,1 millions de dollars 1 , bénéfice net de 13,1 millions de dollars, [...]
Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
24/11/2025
Record Fiscal 2025 Financial Performance: Record net revenues of $107.3 million, adjusted EBITDA of $28.1 million 1 , net income of $13.1 million, operating cash flow of $20 million and free cash flow of $13.7 million 1 [...]
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
24/11/2025
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper [...]
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
24/11/2025
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary [...]

Pages